Metafen Rozkurczowy

Drotaverine Hydrochloride, the active ingredient in Metafen Rozkurczowy, is a phosphodiesterase inhibitor presented as an oral formulation for oral use. It provides smooth muscle relaxation to relieve abdominal, biliary, urinary colic and menstrual cramps in adults.

GNH USA supplies Metafen Rozkurczowy as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Drotaverine Hydrochloride is used to alleviate smooth‑muscle spasm in several gastrointestinal and genitourinary conditions.

- Abdominal pain: reduces discomfort by relaxing intestinal smooth muscle. - Menstrual cramps: eases dysmenorrhea through uterine muscle relaxation. - Biliary colic: diminishes gallbladder spasm‑related pain. - Urinary colic: relieves renal or ureteral colic by relaxing urinary tract smooth muscle.

Drotaverine Hydrochloride may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Headache: mild to moderate intensity. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Allergic reactions: rash, itching, or angioedema. - Severe hypotension: marked blood‑pressure decrease requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm.

When using Drotaverine Hydrochloride, certain precautions should be observed to ensure safety.

- Pregnancy: safety not established; use only if clearly needed. - Breastfeeding: unknown; weigh benefits against potential risks. - Renal impairment: monitor renal function; dose adjustment may be required. - Hepatic impairment: use with caution; monitor liver enzymes. - Elderly: increased sensitivity to hypotension; start with lowest effective dose. - Store at room temperature: keep in original container, protect from moisture and heat.

Drotaverine Hydrochloride can interact with other medicines; awareness of major and moderate interactions helps prevent adverse effects.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase drug exposure. - Other smooth‑muscle relaxants (e.g., papaverine, nifedipine): additive hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents (beta‑blockers, ACE inhibitors): monitor blood pressure. - Anticholinergic drugs: may enhance dry‑mouth sensation.